Alumis Inc. balance sheet
At the end of fiscal 2025, Alumis Inc. had total assets of $412m, total liabilities of $111m and shareholders' equity of $301m. It held $89.7m in cash against $0 of debt: net cash of $89.7m.
Balance sheet
| Fiscal year | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|
| Cash and equivalents | 90 | 64 |
| Total current assets | 318 | 514 |
| Total assets | 412 | 561 |
| Accounts payable | 10 | 13 |
| Deferred revenue (current) | 1 | 7 |
| Total current liabilities | 73 | 76 |
| Total debt | 0 | 0 |
| Total liabilities | 111 | 108 |
| Shareholders' equity | 301 | 452 |
| Net debt (negative = net cash) | −90 | −64 |
| Quarter | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|
| Total current assets | 226 | 518 | 393 | 318 | 532 | 514 |
| Total assets | 261 | 611 | 488 | 412 | 672 | 561 |
| Accounts payable | 7 | 15 | 5 | 10 | 12 | 13 |
| Deferred revenue (current) | — | — | — | 1 | 6 | 7 |
| Total current liabilities | 60 | 86 | 65 | 73 | 71 | 76 |
| Total liabilities | 93 | 126 | 103 | 111 | 105 | 108 |
| Shareholders' equity | 168 | 485 | 385 | 301 | 567 | 452 |
Compare with peers
- Evaxion A/s balance sheet
- Roivant Sciences Ltd. balance sheet
- Adagene Inc. balance sheet
- Tscan Therapeutics, Inc. balance sheet
- Coya Therapeutics, Inc. balance sheet
Head to head: ALMS vs EVAXALMS vs ROIVADAG vs ALMS
More: Biotechnology stocks compared, Health Care sector, rankings of US companies